The therapeutic index (also known as therapeutic ratio), is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes death. Quantitatively, it is the ratio given by the lethal dose divided by the therapeutic dose. A therapeutic index is the lethal dose of a drug for 50% of the population (LD₅₀) divided by the minimum effective dose for 50% of the population (ED₅₀). A high therapeutic index is preferable to a low one: this corresponds to a situation in which one would have to take a much higher dose of a drug to reach the lethal threshold than the dose taken to elicit the therapeutic effect.

Generally, a drug or other therapeutic agent with a narrow therapeutic range (i.e. with little difference between lethal and therapeutic doses) may have its dosage adjusted according to measurements of the actual blood levels achieved in the person taking it. This may be achieved through therapeutic drug monitoring (TDM) protocols. The therapeutic index for diazepam is somewhat forgiving, about = 100. Other drugs, however are much less so, such as Digoxin, which has an index of 2 or 3. ^[1] Other examples of drugs with a narrow therapeutic range, that may require drug monitoring both to achieve therapeutic levels and minimize toxicity, include: dimercaprol, theophylline, warfarin and lithium carbonate. Some antibiotics require monitoring to balance efficacy with minimizing adverse effects, including: gentamicin, vancomycin, amphotericin B, and polymyxin B.

The effective therapeutic index can be affected by targeting, in which the therapeutic agent is concentrated in its area of effect. For example, in radiation therapy for cancerous tumors, shaping the radiation beam precisely to the profile of a tumor in the "beam's eye view" can increase the delivered dose without increasing toxic effects, though such shaping might not change the therapeutic index. Similarly, chemotherapy or radiotherapy with infused or injected agents can be made more efficacious by attaching the agent to an oncophilic substance, as is done in peptide receptor radionuclide therapy for neuroendocrine tumors and in chemoembolization or radioactive microspheres therapy for liver tumors and metastases. This concentrates the agent in the targeted tissues and lowers its concentration in others, increasing efficacy and lowering toxicity.

[edit] See also

• Effective dose
• IC₅₀
• LD₅₀
• EC₅₀
• Certain safety factor
• Protective index

[edit] References

v • d • e Medication > Pharmacology Pharmacokinetics ADME: Absorption • Distribution • Metabolism • Excretion (Clearance) Loading dose • Volume of distribution (Initial) • Rate of infusion Compartment • Bioequivalence • Bioavailability Onset of action • Biological half-life • Plasma protein binding Phase 1 reaction • Phase 2 reaction Therapeutic index (LD50/ED50) Pharmacodynamics Toxicity (Neurotoxicology) • Dose-response relationship (Efficacy, Potency) Antimicrobial pharmacodynamics: Minimum inhibitory concentration/Bacteriostatic • Minimum bactericidal concentration/Bactericide Agonism and antagonism Agonist: Inverse agonist • Irreversible agonist • Partial agonist • Superagonist • Physiological agonist Antagonist: Competitive antagonist • Irreversible antagonist • Physiological antagonist Other Drug tolerance: Tachyphylaxis Drug resistance: Antibiotic resistance • Multiple drug resistance Related fields/subfields Pharmacogenetics • Pharmacogenomics • Neuropsychopharmacology (Neuropharmacology, Psychopharmacology)